oxybutynin has been researched along with Benign Neoplasms in 32 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to evaluate the efficacy of using a quick response (QR) code within video education to guide proper use of fentanyl transdermal patches and control pain, depression, and anxiety levels in cancer patients." | 9.34 | Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial. ( Chen, J; Hu, X; Mao, X; Rao, Y; Xuan, Z; Yang, S; Ye, Z; Zhang, Y, 2020) |
| "The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain." | 9.14 | Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. ( Adile, C; Aielli, F; Ferrera, P; Ficorella, C; Mercadante, S; Porzio, G, 2010) |
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 7.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| "Little is known about the efficacy of low-dose transdermal fentanyl (TDF) patches in opioid-naïve patients with moderate-to-severe cancer pain." | 7.81 | The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. ( Hwang, IG; Kang, JH; Kim, JH; Kim, WS; Lee, HR; Lee, HY; Lee, KE; Oh, SY; Park, K; Park, SH; Park, YS; Song, SY, 2015) |
| "It is unknown whether nutritional status influences pain intensity in cancer patients receiving a transdermal fentanyl patch (FP)." | 7.80 | A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch. ( Chiba, T; Kimura, Y; Kudo, K; Tairabune, T; Takahashi, H; Takahashi, K; Wakabayashi, G, 2014) |
| "Determining the appropriate dose of transdermal fentanyl (TDF) for the alleviation of cancer pain requires determining the factors causing variations in serum fentanyl concentration after TDF treatment." | 7.78 | Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. ( Ebinuma, K; Kokubun, H; Matoba, M; Takayanagi, R; Yago, K; Yamada, Y, 2012) |
| " Compared with other opioids, low-dose fentanyl has been suggested to produce milder side effects such as nausea, constipation, and somnolence." | 7.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 6.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| "We sought to evaluate the efficacy of using a quick response (QR) code within video education to guide proper use of fentanyl transdermal patches and control pain, depression, and anxiety levels in cancer patients." | 5.34 | Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial. ( Chen, J; Hu, X; Mao, X; Rao, Y; Xuan, Z; Yang, S; Ye, Z; Zhang, Y, 2020) |
| "The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain." | 5.14 | Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. ( Adile, C; Aielli, F; Ferrera, P; Ficorella, C; Mercadante, S; Porzio, G, 2010) |
| " Treatment was administered using bicalutamide and leuprorelin acetate, while a transdermal fentanyl (TDF) was applied for pain relief." | 4.31 | Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating. ( Ishii, H; Kanai, A; Kokubun, H; Tabata, KI, 2023) |
| " Lidocaine patches reduce neuropathic pain in postherpetic neuralgia, but their benefits for cancer-related neuropathic pain remain unclear." | 4.31 | Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment. ( Chen, YY; Chiu, GL; Huang, YT; Lai, WS; Lin, PC; Liu, IT; Su, PF; Tsai, JH, 2023) |
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 3.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| "Little is known about the efficacy of low-dose transdermal fentanyl (TDF) patches in opioid-naïve patients with moderate-to-severe cancer pain." | 3.81 | The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. ( Hwang, IG; Kang, JH; Kim, JH; Kim, WS; Lee, HR; Lee, HY; Lee, KE; Oh, SY; Park, K; Park, SH; Park, YS; Song, SY, 2015) |
| "This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl." | 3.80 | Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. ( Bandak, B; Barratt, DT; Christrup, LL; Dale, O; Kaasa, S; Klepstad, P; Somogyi, AA; Tuke, J, 2014) |
| "It is unknown whether nutritional status influences pain intensity in cancer patients receiving a transdermal fentanyl patch (FP)." | 3.80 | A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch. ( Chiba, T; Kimura, Y; Kudo, K; Tairabune, T; Takahashi, H; Takahashi, K; Wakabayashi, G, 2014) |
| "Determining the appropriate dose of transdermal fentanyl (TDF) for the alleviation of cancer pain requires determining the factors causing variations in serum fentanyl concentration after TDF treatment." | 3.78 | Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. ( Ebinuma, K; Kokubun, H; Matoba, M; Takayanagi, R; Yago, K; Yamada, Y, 2012) |
| " Compared with other opioids, low-dose fentanyl has been suggested to produce milder side effects such as nausea, constipation, and somnolence." | 3.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| "In this small study in palliative cancer patients under real-life clinical conditions, the influence of CYP3A on fentanyl variability was investigated." | 2.90 | Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. ( Bardenheuer, HJ; Burhenne, J; Geist, MJP; Mikus, G; Skopp, G; Ziesenitz, VC, 2019) |
| "nausea, constipation, dizziness and headache) were recorded after 6 and 12 days of treatment." | 2.78 | Curative effect of Dingqi analgesic patch on cancer pain: a single-blind randomized controlled trail. ( Bu, J; Du, Y; Fu, T; Huang, X; Lin, J; Tan, W; Wang, C; Wei, G, 2013) |
| " Various retrospective studies comparing dosage changes of buprenorphine and fentanyl patches in persistent pain patients have been completed; however, no long-term prospective, randomized, clinical study has compared the effectiveness of these patches." | 2.78 | A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. ( Chowdhury, S; Mitra, F; Shelley, M; Williams, G, 2013) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 2.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| "NSAIDs may prevent Alzheimer's disease (AD) but have failed as a treatment, possibly because only 1-2% of an oral NSAID dose reaches the brain." | 2.61 | Transspinal delivery of drugs by transdermal patch back-of-neck for Alzheimer's disease: a new route of administration. ( Lehrer, S; Rheinstein, PH, 2019) |
| " However, its low bioavailability and short half-life have restricted its use." | 1.91 | Design, development and evaluation of Resveratrol transdermal patches for breast cancer therapy. ( Gadag, S; Garg, S; Narayan, R; Nayak, UY; Nayak, Y, 2023) |
| "The prevention of venipuncture-induced cancer pain requires a structured training program, which should reflect the views of nurses in clinical practice." | 1.46 | Barriers to venipuncture-induced pain prevention in cancer patients: a qualitative study. ( Chabloz, C; Chirac, A; Collin, C; Filbet, M; Larkin, P; Monsarrat, L; Rhondali, W; Ruer, M, 2017) |
| "The recommended dosing interval for transdermal fentanyl is every 72 h." | 1.43 | A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch. ( Hirayama, Y; Horiuchi, I; Ishitani, K; Kato, J; Koike, K; Kusakabe, T; Machino, T; Mihara, H; Nagasako, T; Nishisato, T; Terui, T; Yamakage, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (75.00) | 24.3611 |
| 2020's | 8 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, H | 3 |
| Kokubun, H | 4 |
| Tabata, KI | 3 |
| Kanai, A | 3 |
| Gadag, S | 1 |
| Narayan, R | 1 |
| Nayak, Y | 1 |
| Garg, S | 1 |
| Nayak, UY | 1 |
| Tsai, JH | 1 |
| Liu, IT | 1 |
| Su, PF | 1 |
| Huang, YT | 1 |
| Chiu, GL | 1 |
| Chen, YY | 1 |
| Lai, WS | 1 |
| Lin, PC | 1 |
| Ando, K | 1 |
| Suzuki, A | 1 |
| Yoshida, H | 1 |
| Geist, MJP | 1 |
| Ziesenitz, VC | 1 |
| Bardenheuer, HJ | 1 |
| Burhenne, J | 1 |
| Skopp, G | 1 |
| Mikus, G | 1 |
| Chiba, T | 2 |
| Takahashi, H | 2 |
| Tairabune, T | 2 |
| Kimura, S | 1 |
| Ueda, H | 1 |
| Kudo, K | 2 |
| Liu, J | 1 |
| Tagami, T | 1 |
| Ozeki, T | 1 |
| Ye, Z | 1 |
| Chen, J | 1 |
| Zhang, Y | 1 |
| Hu, X | 1 |
| Xuan, Z | 1 |
| Yang, S | 1 |
| Mao, X | 1 |
| Rao, Y | 1 |
| Han, X | 1 |
| Li, H | 1 |
| Zhou, D | 1 |
| Chen, Z | 1 |
| Gu, Z | 1 |
| Kim, J | 1 |
| Narayan, RJ | 1 |
| Lu, X | 1 |
| Jay, M | 1 |
| Nguyen, HX | 1 |
| Bozorg, BD | 1 |
| Kim, Y | 1 |
| Wieber, A | 1 |
| Birk, G | 1 |
| Lubda, D | 1 |
| Banga, AK | 1 |
| Zhao, X | 1 |
| Li, X | 1 |
| Zhang, P | 1 |
| Du, J | 1 |
| Wang, Y | 1 |
| Lehrer, S | 1 |
| Rheinstein, PH | 1 |
| Vega, JN | 1 |
| Albert, KM | 1 |
| Mayer, IA | 1 |
| Taylor, WD | 1 |
| Newhouse, PA | 1 |
| Lee, SJ | 1 |
| Lee, HS | 1 |
| Hwang, YH | 1 |
| Kim, JJ | 1 |
| Kang, KY | 1 |
| Kim, SJ | 1 |
| Kim, HK | 1 |
| Kim, JD | 1 |
| Jeong, DH | 1 |
| Paik, MJ | 1 |
| Yee, ST | 1 |
| Wang, C | 1 |
| Tan, W | 1 |
| Huang, X | 1 |
| Fu, T | 1 |
| Lin, J | 1 |
| Bu, J | 1 |
| Wei, G | 1 |
| Du, Y | 1 |
| Liu, HW | 1 |
| Huang, CC | 1 |
| Barratt, DT | 1 |
| Bandak, B | 1 |
| Klepstad, P | 1 |
| Dale, O | 1 |
| Kaasa, S | 1 |
| Christrup, LL | 1 |
| Tuke, J | 1 |
| Somogyi, AA | 1 |
| Ryazhenov, VV | 1 |
| Abuzarova, GR | 1 |
| Gorokhova, SG | 1 |
| Emchenko, IV | 1 |
| Matveev, NV | 1 |
| Kimura, Y | 1 |
| Wakabayashi, G | 1 |
| Takahashi, K | 1 |
| Kang, JH | 1 |
| Oh, SY | 1 |
| Song, SY | 1 |
| Lee, HY | 1 |
| Kim, JH | 1 |
| Lee, KE | 1 |
| Lee, HR | 1 |
| Hwang, IG | 1 |
| Park, SH | 1 |
| Kim, WS | 1 |
| Park, YS | 1 |
| Park, K | 1 |
| Koike, K | 1 |
| Terui, T | 1 |
| Nagasako, T | 1 |
| Horiuchi, I | 1 |
| Machino, T | 1 |
| Kusakabe, T | 1 |
| Hirayama, Y | 1 |
| Mihara, H | 1 |
| Yamakage, M | 1 |
| Kato, J | 1 |
| Nishisato, T | 1 |
| Ishitani, K | 1 |
| Filbet, M | 1 |
| Larkin, P | 1 |
| Chabloz, C | 1 |
| Chirac, A | 1 |
| Monsarrat, L | 1 |
| Ruer, M | 1 |
| Rhondali, W | 1 |
| Collin, C | 1 |
| Nomura, M | 1 |
| Kamata, M | 1 |
| Kojima, H | 1 |
| Hayashi, K | 1 |
| Kozai, M | 1 |
| Sawada, S | 1 |
| Mercadante, S | 1 |
| Porzio, G | 1 |
| Ferrera, P | 1 |
| Aielli, F | 1 |
| Adile, C | 1 |
| Ficorella, C | 1 |
| Hata, A | 1 |
| Katakami, N | 1 |
| Masuda, Y | 1 |
| Nanjo, S | 1 |
| Otsuka, K | 1 |
| Kaji, R | 1 |
| Fujita, S | 1 |
| Iwamori, S | 1 |
| Mifune, Y | 1 |
| Orita, H | 1 |
| Fukae, M | 1 |
| Yamatani, T | 1 |
| Garbe, E | 1 |
| Jobski, K | 1 |
| Schmid, U | 1 |
| Przeklasa-Muszyńska, A | 1 |
| Dobrogowski, J | 1 |
| Ebinuma, K | 1 |
| Matoba, M | 1 |
| Takayanagi, R | 1 |
| Yamada, Y | 1 |
| Yago, K | 1 |
| López Ramírez, E | 1 |
| Takakuwa, O | 1 |
| Oguri, T | 1 |
| Maeno, K | 1 |
| Yokoyama, M | 1 |
| Hijikata, H | 1 |
| Uemura, T | 1 |
| Ozasa, H | 1 |
| Ohkubo, H | 1 |
| Miyazaki, M | 1 |
| Niimi, A | 1 |
| Mitra, F | 1 |
| Chowdhury, S | 1 |
| Shelley, M | 1 |
| Williams, G | 1 |
1 review available for oxybutynin and Benign Neoplasms
| Article | Year |
|---|---|
Transspinal delivery of drugs by transdermal patch back-of-neck for Alzheimer's disease: a new route of administration.
Topics: Administration, Cutaneous; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antineoplasti | 2019 |
8 trials available for oxybutynin and Benign Neoplasms
| Article | Year |
|---|---|
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cytochrome P-450 CYP3A; Female; Fentanyl; | 2019 |
Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Female; Fentanyl; Health Education; Humans; Male; Middle Ag | 2020 |
Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Survivors; Co | 2019 |
Curative effect of Dingqi analgesic patch on cancer pain: a single-blind randomized controlled trail.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Drugs, Chinese Herbal; Female; Humans; Male; | 2013 |
Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Chronic Disease; Double-Blind Method; Female; F | 2011 |
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
Topics: Aged; Analgesia; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; Mal | 2010 |
Transdermal buprenorphine in the treatment of cancer and non-cancer pain - the results of multicenter studies in Poland.
Topics: Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Huma | 2011 |
A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Disease; Chronic Pain; | 2013 |
23 other studies available for oxybutynin and Benign Neoplasms
| Article | Year |
|---|---|
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Design, development and evaluation of Resveratrol transdermal patches for breast cancer therapy.
Topics: Administration, Cutaneous; Animals; Female; Neoplasms; Povidone; Rats; Resveratrol; Skin; Skin Absor | 2023 |
Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment.
Topics: Analgesics; Analgesics, Opioid; Humans; Lidocaine; Neoplasms; Neuralgia; Pain Measurement; Prospecti | 2023 |
Possible Effect of Blonanserin Transdermal Patch on Antiemetic Control in Patients With Terminal Cancer with Refractory Nausea.
Topics: Antiemetics; Antipsychotic Agents; Ascites; Humans; Nausea; Neoplasms; Transdermal Patch; Vomiting | 2023 |
Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Topics: Aged; Analgesics, Opioid; Cachexia; Cancer Pain; Female; Fentanyl; Humans; Male; Middle Aged; Morphi | 2020 |
Fabrication of 3D-Printed Fish-Gelatin-Based Polymer Hydrogel Patches for Local Delivery of PEGylated Liposomal Doxorubicin.
Topics: Bioprinting; Doxorubicin; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Stability; | 2020 |
Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Disease Models, Animal; Drug Delivery Systems; Extra | 2020 |
Neutron-activatable needles for radionuclide therapy of solid tumors.
Topics: Brachytherapy; Coated Materials, Biocompatible; Drug Delivery Systems; Equipment Design; Holmium; Hu | 2017 |
Poly (vinyl alcohol) microneedles: Fabrication, characterization, and application for transdermal drug delivery of doxorubicin.
Topics: Administration, Cutaneous; Antibiotics, Antineoplastic; Cadaver; Doxorubicin; Drug Compounding; Drug | 2018 |
Tip-loaded fast-dissolving microneedle patches for photodynamic therapy of subcutaneous tumor.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Cell Line, Tumor; Drug Carriers; Drug Deliv | 2018 |
Enhanced anti-tumor immunotherapy by dissolving microneedle patch loaded ovalbumin.
Topics: Administration, Cutaneous; Animals; Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes | 2019 |
Rapid and sensitive controlled release monitoring method of biomedical combined products with IDM for pain management and cancer treatment.
Topics: Analgesics; Antineoplastic Agents; Calibration; Calorimetry, Differential Scanning; Chromatography, | 2014 |
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily D, M | 2014 |
[Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: pharmacoeconomic aspects].
Topics: Ambulances; Analgesics, Opioid; Cost-Benefit Analysis; Economics, Pharmaceutical; Fentanyl; Health C | 2014 |
A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Neo | 2014 |
The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2015 |
A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Sectional Studies; Fem | 2016 |
Barriers to venipuncture-induced pain prevention in cancer patients: a qualitative study.
Topics: Adult; Analgesia; Attitude of Health Personnel; Clinical Competence; Clinical Protocols; Female; Hum | 2017 |
[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Male; Mi | 2011 |
Utilisation of transdermal fentanyl in Germany from 2004 to 2006.
Topics: Aged; Analgesics, Opioid; Databases, Factual; Dose-Response Relationship, Drug; Female; Fentanyl; Ge | 2012 |
Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Cytochrome P-450 CYP3A; Dose-Response Re | 2012 |
Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience.
Topics: Acute Pain; Aged; Aged, 80 and over; Anesthetics, Local; Chronic Pain; Female; Humans; Lidocaine; Ma | 2013 |
Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.
Topics: Administration, Cutaneous; Analgesics, Opioid; Citric Acid; Fentanyl; Humans; Lung Neoplasms; Neopla | 2013 |